Join Growin Stock Community!

Myriad genetics, inc.MYGN.US Overview

US StockHealthcare
(No presentation for MYGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MYGN AI Insights

MYGN Overall Performance

MYGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MYGN Recent Performance

7.92%

Myriad genetics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MYGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MYGN Key Information

MYGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MYGN Profile

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Price of MYGN

MYGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MYGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.93
PE Ratio (TTM)
-
Forward PE
23.62
PS Ratio (TTM)
0.52
PB Ratio
1.22
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.93%
Net Margin
-44.38%
Revenue Growth (YoY)
-1.56%
Profit Growth (YoY)
-1.50%
3-Year Revenue Growth
5.67%
3-Year Profit Growth
5.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.93
PE Ratio (TTM)
-
Forward PE
23.62
PS Ratio (TTM)
0.52
PB Ratio
1.22
Price-to-FCF
-
Gross Margin
69.93%
Net Margin
-44.38%
Revenue Growth (YoY)
-1.56%
Profit Growth (YoY)
-1.50%
3-Year Revenue Growth
5.67%
3-Year Profit Growth
5.82%

  • When is MYGN's latest earnings report released?

    The most recent financial report for Myriad genetics, inc. (MYGN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MYGN's short-term business performance and financial health. For the latest updates on MYGN's earnings releases, visit this page regularly.

  • What is the operating profit of MYGN?

    According to the latest financial report, Myriad genetics, inc. (MYGN) reported an Operating Profit of -5.7M with an Operating Margin of -2.72% this period, representing a growth of 85.38% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MYGN's revenue growth?

    In the latest financial report, Myriad genetics, inc. (MYGN) announced revenue of 209.8M, with a Year-Over-Year growth rate of -0.38%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MYGN have?

    As of the end of the reporting period, Myriad genetics, inc. (MYGN) had total debt of 209.8M, with a debt ratio of 0.3. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MYGN have?

    At the end of the period, Myriad genetics, inc. (MYGN) held Total Cash and Cash Equivalents of 149.6M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MYGN go with three margins increasing?

    In the latest report, Myriad genetics, inc. (MYGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 70%%, operating margin of -2.72%%, and net margin of -3.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MYGN's profit trajectory and future growth potential.

  • Is MYGN's EPS continuing to grow?

    According to the past four quarterly reports, Myriad genetics, inc. (MYGN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MYGN?

    Myriad genetics, inc. (MYGN)'s Free Cash Flow (FCF) for the period is 4.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 557.14% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MYGN?

    The latest valuation data shows Myriad genetics, inc. (MYGN) has a Price-To-Earnings (PE) ratio of -1.13 and a Price/Earnings-To-Growth (PEG) ratio of 0.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.